maat pharma - Robuta Search

https://www.maatpharma.com/ MaaT Pharma, the leading microbiome company in oncology Jun 25, 2026 - We are a late stage microbiome company aiming to improve survival in cancer. maat pharma leading microbiome company oncology https://www.eib.org/en/registers/all/246018749 MAAT PHARMA (IEU-LS) maat pharma ieu ls https://www.businesswire.com/news/home/20250724345351/en/MaaT-Pharma-Half-year-Report-to-the-Liquidity-Contract-With-Kepler-Cheuvreux MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux maat pharma to the https://www.benzinga.com/quote/MATPF/short-interest MAAT PHARMA SA by MAAT PHARMA SA Stock Short Interest Report | OTC:MATPF | Benzinga Short interest for MAAT PHARMA SA by MAAT PHARMA SA gives investors a sense of the degree to which investors are betting on the decline of MAAT PHARMA SA by... maat pharma by stock short interest sa https://www.businesswire.com/news/home/20201126005524/en/MaaT-Pharma-to-Provide-Data-Update-for-Lead-Microbiome-Biotherapeutic-in-Oral-Presentation-at-62nd-American-Society-of-Hematology-ASH-Annual-Meeting MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd... MaaT Pharma announced today that updated results from its compassionate use program for lead microbiome therapeutic MaaT013 will be reported in an oral prese... https://www.businesswire.com/news/home/20260331625825/en/MaaT-Pharma-Announces-Publication-of-Retrospective-Data-in-Third-Line-Acute-GvHD-from-the-CHRONOS-Study-in-Bone-Marrow-Transplantation-Journal MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS... MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal. https://www.biospace.com/maat-pharma-announces-first-dsmb-positive-review-of-ongoing-phase-2-clinical-trial-evaluating-maat033-for-patients-receiving-allo-hsct MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating... phase 2 clinical trial https://www.businesswire.com/news/home/20250428460883/en/MaaT-Pharma-Presents-Preclinical-Data-at-AACR-Annual-Meeting-Demonstrating-Immune-Activation-and-Anti-Tumor-Activity-of-MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and... MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 aacr annual meeting https://www.businesswire.com/news/home/20250513051655/en/MaaT-Pharma-Provides-Business-Update-and-Reports-Financial-Results-for-the-First-Quarter-2025 MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025